Neurocrine Biosciences (NASDAQ:NBIX) PT Lowered to $114.00 at BMO Capital Markets

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) had its price target decreased by stock analysts at BMO Capital Markets from $128.00 to $114.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a "market perform" rating on the stock. BMO Capital Markets' price target points to a potential downside of 3.76% from the company's current price.

A number of other analysts have also commented on the company. Barclays cut their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating on the stock in a research note on Monday, September 9th. Raymond James restated an "outperform" rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a report on Thursday, August 29th. Oppenheimer increased their price objective on Neurocrine Biosciences from $216.00 to $219.00 and gave the company an "outperform" rating in a report on Friday, August 2nd. Finally, StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Sunday, August 4th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Stock Up 0.1 %

Shares of NBIX stock traded up $0.11 on Thursday, reaching $118.46. The company had a trading volume of 728,016 shares, compared to its average volume of 852,300. The stock has a market capitalization of $11.92 billion, a PE ratio of 32.63 and a beta of 0.36. The business's 50-day moving average is $126.60 and its 200 day moving average is $134.98. Neurocrine Biosciences has a one year low of $103.63 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $1.15 by ($0.52). The company had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The business's quarterly revenue was up 30.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.95 EPS. On average, sell-side analysts forecast that Neurocrine Biosciences will post 4.19 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Julie Cooke sold 12,632 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the completion of the sale, the insider now owns 18,202 shares in the company, valued at $2,789,638.52. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Julie Cooke sold 12,632 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the completion of the transaction, the insider now directly owns 18,202 shares in the company, valued at $2,789,638.52. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ingrid Delaet sold 273 shares of the company's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total transaction of $40,322.10. Following the completion of the sale, the insider now owns 6,607 shares in the company, valued at $975,853.90. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,968 shares of company stock worth $8,999,632 in the last three months. Company insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Mather Group LLC. purchased a new position in Neurocrine Biosciences during the 1st quarter worth $26,000. RFP Financial Group LLC boosted its holdings in Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after purchasing an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in Neurocrine Biosciences in the 2nd quarter worth about $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences in the 2nd quarter worth about $30,000. Finally, New Covenant Trust Company N.A. purchased a new stake in Neurocrine Biosciences in the 1st quarter valued at about $32,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.